CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)
N/A
The main objective of this national study is to evaluate the virological su...
Status
Not Yet Recruiting
Location
Victor Dupuy Hospital
Start Date
2026-03-15
Trial ID
NCT07402044
Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)
PHASE2
This study is a Phase IIa, randomized, multi-site, two-arm, double-blinded ...
Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.
N/A
The RELATIVITY study is a nationwide, multicenter, ambispective observation...
Status
Active Not Recruiting
Location
Hospital Universitario de Burgos
Start Date
2024-12-31
Trial ID
NCT07703748
Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.
PHASE3
The purpose of this study is to evaluate if offering long-acting injectable...
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
PHASE3
This Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLA...